Education
About Us
Working with TipRanks
Follow Us
BioVaxys Technology (TSE:BIOV)
:BIOV
BIOV Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.09
Previous CloseN/A
Volume0.00
Average Volume (3M)120.78K
Market Cap
$14.58M
Enterprise ValueC$13.90M
Total Cash (Recent Filing)C$334.97K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Jun 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding291,525,200
10 Day Avg. Volume61,972
30 Day Avg. Volume120,779
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
BioVaxys Technology News
PremiumCompany Announcements
BioVaxys Technology Corp. Updates on Management Cease Trade Order Status
PremiumCompany Announcements
BioVaxys Settles Debt and Closes Final Private Placement Tranche
PremiumCompany Announcements
BioVaxys Faces Potential Filing Delay Amid Recent Acquisitions
PremiumCompany Announcements
BioVaxys Extends Private Placement Closing Date to February 14, 2025
PremiumCompany Announcements
BioVaxys Extends Private Placement Offering Deadline
PremiumCompany Announcements
BioVaxys Advances DPX Technology for mRNA Vaccine DeliveryPremiumCompany Announcements
BioVaxys Technology to Present at Emerging Growth Conference---
Options Prices
Currently, No data available
---
Ownership Overview
11.41% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
88.59% Public Companies and
Individual Investors
BIOV FAQ
What was BioVaxys Technology’s price range in the past 12 months?
BioVaxys Technology lowest stock price was C$0.04 and its highest was C$0.09 in the past 12 months.
What is BioVaxys Technology’s market cap?
BioVaxys Technology’s market cap is $14.58M.
When is BioVaxys Technology’s upcoming earnings report date?
BioVaxys Technology’s upcoming earnings report date is Jun 26, 2025 which is in 87 days.
How were BioVaxys Technology’s earnings last quarter?
Currently, no data Available
Is BioVaxys Technology overvalued?
According to Wall Street analysts BioVaxys Technology’s price is currently Overvalued.
Does BioVaxys Technology pay dividends?
BioVaxys Technology does not currently pay dividends.
What is BioVaxys Technology’s EPS estimate?
BioVaxys Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVaxys Technology have?
BioVaxys Technology has 291,525,200 shares outstanding.
What happened to BioVaxys Technology’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of BioVaxys Technology?
Currently, no hedge funds are holding shares in TSE:BIOV
---
Company Description
BioVaxys Technology
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. The company is based in Vancouver, Canada.
---
Technical Analysis
---